Latest news:

Follicum AB receives Notice of Allowance from the U.S. Patent Office for method of stimulating hair growth with FOL-005

Follicum AB (“Follicum”) announces that the U.S. Patent Office (USPTO) has issued a Notice of Allowance for their patent application 16/176,201 which when granted confers expanded protection for Follicum’s product candidate FOL-005. Follicum has already two granted US patents in this patent family (US 9,381,149 and US 10,137,169), conferring protection for different forms of FOL-005. […]

Sign up for our Newsletter

Follicum’s compliance with GDPR. Read more

Hair growth

Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.

Read more


Follicums pre-clinical research has resulted in a new peptide class which increased the release of insulin on mice

Read more


We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more




11 Nov 19
BIO Europe

Follicum will attend the BIO Europe conference in Hamburg 11-13 November 2019 More information will...